Strap muscle invasion in differentiated thyroid cancer does not impact disease-specific survival: a population-based study

Ja Kyung Yoon1, Jandee Lee2, Eun-Kyung Kim1, Jung Hyun Yoon1, Vivian Youngjean Park1, Kyunghwa Han1,3* & Jin Young Kwak1*

The American Joint Committee on Cancer (AJCC) 8th TNM staging system of differentiated thyroid cancer defines gross strap muscle invasion as T3b stage. However, the impact of strap muscle invasion on disease-specific survival (DSS) remains controversial. To elucidate the survival impact of strap muscle invasion of any degree in thyroid cancers, the Surveillance, Epidemiology, and End Results (SEER) database (1973–2018) was queried for thyroid cancer only patients on July 2019 (n = 19,914). The Cox proportional hazard analysis with multivariable adjustment revealed that strap muscle invasion was not a significant factor for DSS in tumors equal to or smaller than 40 mm (hazard ratio (HR) = 1.620 [confidence interval (CI) 0.917 – 2.860]; p = 0.097). The competing risk analysis with multivariable adjustment showed that strap muscle invasion did not significantly impact DSS regardless of tumor size or cause of death (cancer-caused death (Subdistribution HR (SDHR) = 1.567 [CI 0.984 – 2.495]; p = 0.059); deaths to other causes (SDHR = 1.155 [CI 0.842 – 1.585]; p = 0.370). A “modified” staging schema discarding strap muscle invasion as a T stage criterion showed better 10-year DSS distinction between T stages. The modified staging schema may better reflect cancer-caused death risk and may prevent potential overstaging.

Extrathyroidal extension (ETE) is defined as the direct extension of the primary thyroid cancer into the adjacent structures, including strap muscles, trachea, larynx, esophagus, recurrent laryngeal nerve and/or major vasculature1. While strap muscle invasion was subclassified as minimal or gross, the American Joint Committee on Cancer (AJCC) 8th edition TNM staging schema discarded the minimal ETE category entirely while defining gross strap muscle invasion alone as the T3b stage. Validation studies have corroborated the new staging system by showing better allocation of relatively low-risk patients into lower stages with excellent survival outcomes3, and high-risk patients into more advanced stages1–3.

The newly introduced staging factor of gross strap muscle invasion alone (T3b) has been associated with higher risk of positive resection margin, bigger tumor size, higher recurrence rate, and lower disease survival rate4–10. However, studies have reported that strap muscle invasion alone, both minimal and gross, may not have significant influence on overall survival11,12, particularly in tumors equal to or smaller than 40 mm13. A recent study has also suggested similar disease-free survival rate between the minimal ETE and gross strap muscle invasion alone groups in papillary thyroid carcinomas with tumor size 10- to 40-mm14. With advances in surgical techniques and adjuvant therapies15, it is possible that tumors with strap muscle invasion alone may indeed have better prognosis than previously anticipated. Therefore, the impact of strap muscle invasion alone, both minimal and gross, on the survival of thyroid cancer patients needs to be elucidated to accurately allocate patients into appropriate staging groups according to individual risk, which will ensure longer disease-free survival and prevent overtreatment.

The Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute (NCI) collects cancer incidence and survival information from population-based cancer registries encompassing nearly 34.6% of the total population of the United States15. The SEER program is regarded as a critical database for

1Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, South Korea. 2Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. 3Center for Clinical Imaging Data Science, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, South Korea. *email: khhan@yuhs.ac; docjim@yuhs.ac
cancer survival surveillance in the United States. This openly available database has compiled cancer incidence and survival data since 1973. Accordingly, it is an ideal database for analyzing the effect of gross ETE on overall survival in thyroid cancer.

Therefore, the purpose of this study was to explore the impact of strap muscle invasion alone, both minimal and gross, on the disease-specific survival (DSS) of differentiated thyroid cancer (DTC) patients using the SEER database, and to potentially improve the survival prediction power of the TNM staging schema.

Results
Baseline characteristics. Baseline patient demographics are presented in Table 1. The median age at diagnosis was 47.0 years old (interquartile range, 36.0–57.0 years old), with a median follow-up of 55.0 months (interquartile range, 32.0–85.0 months; range, 1.0–155.0 months). A total of 18,085 (90.8%) patients were diagnosed with papillary carcinoma and its variants, while 1406 (7.1%) patients were diagnosed with follicular carcinoma and its variants. Other pathologies included oxyphilic adenocarcinoma (n = 355), non-encapsulated sclerosing carcinoma (n = 64), and clear cell adenocarcinoma (n = 4). Most patients underwent total thyroidectomy (n = 16,874, 84.7%). Adjuvant radiation therapy was performed in over half of the patients (n = 10,165, 51.0%), which included radioactive iodine (RAI) (n = 9740), radioactive implants (n = 120), beam radiation (n = 195), a combination of beam radiation with implants or isotopes (n = 66), and radiation therapy not otherwise specified (n = 44). Adjuvant chemotherapy was performed in only 57 (0.3%) patients. The distribution of T stage according to the AJCC 8th staging criteria is shown in Table 2.

Table 1. Baseline patient demographics. Data are presented as numbers (%) unless indicated otherwise. ICD-O-3 International Classification of Diseases for Oncology, LN lymph node. a Data are shown as medians (1st quartile, 3rd quartile).

| Patient characteristics | Value |
|-------------------------|-------|
| **Age at diagnosis**    | 47    |
| ≤ 55 years old          | 13,688|
| ≥ 55 years old          | 6226  |
| **Sex**                 |       |
| Male                    | 4658  |
| Female                  | 15,256|
| **Race**                |       |
| White                   | 16,063|
| Black                   | 1371  |
| Other                   | 2486  |
| **Tumor size (mm)**     | 15    |
| (8.0, 26.0)             |       |
| **Pathology according to ICD-O-3** |       |
| Papillary carcinoma     | 18,085|
| Follicular carcinoma    | 1406  |
| Other                   | 423   |
| Multifocal              | 8213  |
| **Extrathyroidal extension (ETE)** |       |
| No or minimal invasion  | 17,703|
| Strap muscle invasion alone | 1552  |
| Major organ invasion    | 464   |
| Major vessel invasion   | 195   |
| LN metastasis           | 4897  |
| Distant metastasis      | 229   |
| Total thyroidectomy     | 16,874|
| Radiation therapy       | 10,165|
| Chemotherapy            | 57    |
| Follow-up months*       | 55    |
| (32.0, 85.0)            |       |

Prognostic impact of strap muscle invasion alone on 10-year DSS. Cox proportional hazard analysis was performed to estimate the prognostic impact of strap muscle invasion on DSS in all patients (n = 19,914) and in the subgroup of patients with tumor size equal to or smaller than 40 mm (n = 17,837) (Table 3). Univariable and multivariable analyses revealed that strap muscle invasion alone as well as age, tumor size, major organ invasion, major vessel invasion, LN metastasis, distant metastasis, and chemotherapy were significant prognostic factors for DSS. Subgroup analysis of tumors equal to or smaller than 40 mm in size showed that although strap muscle invasion alone was a significant prognostic factor for DSS on univariable Cox regression analysis, it was not a significant prognostic factor for DSS on multivariable analysis.
Competing risk analysis of cancer-caused deaths and deaths to other causes. On multivariable competing risk analysis, strap muscle invasion alone did not significantly impact death due to either cancer or other causes in all patients as well as in the subgroup of tumors equal to or smaller than 40 mm (Table 4), although it was a significant factor on univariable analysis (Supplementary Table S1). In addition, in the subgroup of patients 55 years old of age or older, multivariable competing risk analysis showed that strap muscle invasion only did not significantly impact death due to any cause, despite its significance on univariable competing risk analysis (Supplementary Table S2).

10-year DSS according to the T stages of the AJCC 8th TNM staging and the modified TNM staging schemas. Table 2 showed the 10-year DSS and the number of patients in each T stage according to either the AJCC 8th TNM staging schema or the “modified” TNM staging schema (discarding the strap muscle invasion factor from the T stage criteria). While there was an overall negative correlation between T stage and 10-year DSS per the AJCC 8th staging schema, the T3b stage showed better 10-year DSS than the T3a stage (Fig. 1a). Restaging of the T3b stage (i.e., T3bNanMyM0) according to the modified TNM staging schema resulted in a total of 1552 patients assigned to T1a (n = 238, 15.3%), T1b (n = 543, 35.0%), T2 (n = 506, 32.6%), and T3 (n = 265, 17.1%) stages with significant difference in DSS (Fig. 1b). Among the 1518 patients without distant metastasis (i.e., T3bNanM0, stage II), 589 patients (38.8%) were downstaged to stage I, and there was significant difference in DSS after reallocation into either stage I or stage II (Fig. 1c,d). T stage and overall staging reallocation per the modified staging schema is shown in Fig. 2.

Evaluation of the power of survival prediction for the AJCC 8th and the modified TNM staging schemas. The Harrell’s C concordance indices (C-indices) of the AJCC 8th and the modified TNM staging schemas was estimated as 0.9418 and 0.9405, respectively, but without statistically significant difference (p = 0.220). The proportion of variance explained (PVE) for DSS prediction with the AJCC 8th and the modified TNM staging schemas was estimated as 4.45% and 4.43%, respectively.

Discussion
This study suggested that strap muscle invasion alone of any degree was not a statistically significant prognostic factor of DSS in all tumor sizes of DTC. In particular, this finding may significantly impact tumors equal to or smaller than 40 mm, which may be overstaged by the current AJCC 8th TNM staging schema. In addition, survival analysis of the T3b group according to the AJCC 8th TNM staging schema showed that it consists of a heterogeneous group of patients with significantly different DSS according to tumor size. T3b patients reallocated to either the T1 or T2 stage according to the suggested modified staging schema showed significantly better DSS compared to those in the T3 stage.

Historically, ETE was assumed to have a positive correlation with compromised survival in DTC, but with some controversy. While minimal ETE was totally discarded from the AJCC 8th TNM staging schema, gross strap muscle invasion was introduced as the new T3b stage regardless of tumor size. However, there have been suggestions that even gross strap muscle invasion does not impact survival in patients with DTC. Indeed, the AJCC 8th staging schema contains in-stage heterogeneity in regards to DSS prediction. One potential source of this heterogeneity may be due to the prognostic impact of strap muscle invasion. A recent study of a total
Table 3. Cox proportional hazard analysis for disease-specific survival (DSS) according to the AJCC 8th TNM staging schema. Statistically significant values are shown in bold. DSS disease-specific survival, HR hazards ratio, CI confidence interval, ETE extrathyroidal extension, LN lymph node.

| Variables                        | All patients (n = 19,914) | Tumor size ≤ 40 mm (n = 17,837) |
|----------------------------------|---------------------------|---------------------------------|
|                                  | Univariable               | Multivariable                  | Univariable               | Multivariable                  |
|                                  | HR (95% CI) p value       | HR (95% CI) p value            | HR (95% CI) p value       | HR (95% CI) p value            |
| Age                              | 1.089 (1.079, 1.100)      | < 0.001                        | 1.068 (1.058, 1.078)      | < 0.001                        |
| Male sex                         | 2.396 (0.322, 0.541)      | < 0.001                        | 1.197 (0.636, 1.098)      | 0.196                          |
| Race                             |                           |                                 |                           |                                |
| White                            | Reference                 | –                               | Reference                 | –                               |
| Black                            | 0.688 (1.453, 0.364)      | 0.250                          | 0.624 (0.229, 1.698)      | 0.356                          |
| Others                           | 1.192 (0.827, 1.717)      | 0.346                          | 1.375 (0.839, 2.252)      | 0.206                          |
| Primary tumor size               |                           |                                 |                           |                                |
| ≤ 10 mm                          | Reference                 | Reference                       | Reference                 | Reference                       |
| 10 < size ≤ 20 mm                | 2.421 (1.315, 4.457)      | 0.005                          | 2.021 (1.088, 3.756)      | 0.026                          |
| 20 < size ≤ 40 mm                | 5.886 (3.365, 10.296)     | < 0.001                        | 3.821 (2.146, 6.803)      | < 0.001                        |
| > 40 mm                          | 25.546 (14.923, 43.732)   | < 0.001                        | 7.613 (4.276, 13.554)     | < 0.001                        |
| ETE                              |                           |                                 |                           |                                |
| No or minimal                    | Reference                 | Reference                       | Reference                 | Reference                       |
| Strap muscle invasion only       | 3.278 (2.191, 4.904)      | < 0.001                        | 1.592 (1.044, 2.427)      | 0.031                          |
| Major organ invasion             | 16.228 (11.513, 22.875)   | < 0.001                        | 2.933 (1.925, 4.467)      | < 0.001                        |
| Major vessel invasion            | 36.492 (25.812, 51.592)   | < 0.001                        | 4.284 (2.824, 6.500)      | < 0.001                        |
| Multifocality                    | 1.078 (0.713, 1.527)      | 0.576                          | –                         | –                              |
| LN metastasis                    | 3.628 (2.804, 4.693)      | < 0.001                        | 1.783 (1.307, 2.431)      | < 0.001                        |
| Distant metastasis               | 50.060 (37.600, 66.663)   | < 0.001                        | 6.439 (4.590, 9.034)      | < 0.001                        |
| Total thyroidectomy              | 1.124 (0.781, 1.617)      | 0.529                          | –                         | –                              |
| Radiation therapy                | 2.486 (1.856, 3.330)      | < 0.001                        | 1.177 (0.864, 1.605)      | 0.301                          |
| Chemotherapy                     | 30.070 (17.814, 50.755)   | < 0.001                        | 4.945 (2.719, 9.896)      | < 0.001                        |

of 2804 patients and demonstrated that perithyroidal soft tissue or strap muscle invasion showed disease-free survival, overall survival and DSS comparable to those of intrathyroidal tumors equal to or smaller than 40 mm (median follow-up 59 months; range, 12–192 months), although with small number of strap muscle invasion cases (n = 61)13. Another study on 3104 patients with either papillary or follicular thyroid carcinoma revealed that gross strap muscle invasion does not significantly impact DSS in tumors equal to or smaller than 40 mm, and that DSS of the T3b stage did not significantly differ from that of the T2 stage (median follow-up 10 years; interquartile range, 8.1–12 years)13.

This population-based study utilized the SEER database14 without discrimination of tumor size to reveal that strap muscle invasion alone does not significantly impact DSS, regardless of tumor size or cause of death. This may have particular clinical impact on tumors equal to or smaller than 40 mm which may be appropriately downstaged. Although the estimated C-indices and PVE did not reveal statistically significant differences in the predictive power of the current AJCC 8th and the suggested modified TNM staging schemas, better survival curve separation was observed per the modified staging schema with statistical significance.

Invasion of strap muscle in any degree may not have significant survival impact due to the relative complexity of posterior anatomical structures such as trachea, recurrent laryngeal nerve, and prevertebral fascia. Critical laryngotracheal structure invasion leads to a higher possibility of incomplete resection and therefore to higher clinical recurrence and poorer prognosis4. On the other hand, strap muscles can be relatively easily resected in the presence of tumor invasion13,22, accounting for their lack of significant impact on DSS. Consequently, anterior or posterior ETE have been suggested as more appropriate staging factors than gross strap muscle invasion16,23. Therefore, the dismissal of both minimal and gross strap muscle invasion may lead to better allocation by the
TNM staging schema and better reflection of DSS, as suggested by the modified staging schema, particularly for tumors equal to or smaller than 40 mm.

There are several limitations to our study. First, the retrospective nature of this study may have caused an inherent bias. Second, the SEER database did not distinguish between minimal and gross strap muscle invasion. However, any ETE beyond strap muscle invasion was explicitly recorded and an inference was made that the code for strap muscle invasion included both minimal and gross strap muscle invasion collectively. Thus, the purpose of this study was limited to exploring the potential changes in TNM staging with the collective dismissal of both minimal and gross strap muscle invasions. Third, the SEER database did not include recurrence data, which limited the analysis of the impact of strap muscle invasion alone on disease-free survival. Strengths of the present study include the use of a national, comprehensive database with analyses of prognostic variables in all tumor size groups as well as tumor size and age subgroups. Moreover, competing risk analysis offered a more accurate evaluation of potential prognostic variables relative to other causes of death.

In conclusion, strap muscle invasion alone of any degree does not significantly impact DSS in DTC patients, regardless of tumor size. The modified TNM staging schema suggests potential modification of the TNM staging particularly for tumors equal to or smaller than 40 mm.

**Methods**

**SEER database and study population.** The SEER database was accessed on July 4th, 2019, and queried for all patients diagnosed with DTC alone. Inclusion criteria were as follows: (1) patients older than 18 years old, (2) patients diagnosed with only DTC according to the International Classification of Disease for Oncology, third edition (ICD-O-3) codes (Supplementary Table S3), and (3) patients who underwent surgery with or without adjuvant radiation therapy or chemotherapy. Patients with medullary carcinoma, mixed medullary carcinoma component, insular carcinoma, and anaplastic thyroid cancer were excluded. In addition, patients with unknown race, unknown tumor grade, unknown ETE, unavailable or incomplete TNM staging data, death certificate or autopsy alone, or unknown cause of death were excluded (Fig. 3). The extension item of the SEER Cancer Schema (CS) version 02.05.50, which encodes tumor ETE based on pathologic and/or clinical information, does not explicitly distinguish between minimal or gross strap muscle invasion. However, since more advanced
organ invasion (i.e., recurrent laryngeal nerve, vagus nerve, major vessels, major organs or prevertebral fascia) was clearly distinguished by the CS extension coding, the invasion of omohyoid, sternohyoid, sternothyroid and/or thyrohyoid muscles (code 450) was considered to include both minimal and gross strap muscle invasion collectively. This code was regarded as the T3b stage per the AJCC 8th TNM staging schema in this study.

A total of 19,914 patients were included in the final analysis of demographic variables including age at diagnosis, race, sex, year of diagnosis and survival status. Pathologic characteristics included single or multifocal disease, tumor size, ETE, LN metastasis and distant metastasis. This retrospective study utilizing a publicly available database with de-identified records did not require informed consent from the SEER registered cases, and Institutional Review Board approval was formally waived.

**Primary outcome.** The primary outcome of this study was cancer-caused death from DTC. DSS was defined as the time from date of diagnosis until cancer-caused death or last censoring.

**Tumor staging.** Because the currently available SEER database only provides TNM staging according to the AJCC 7th or previous staging schemas, the included 19,914 patients were restaged according to the AJCC 8th TNM staging schema using the recorded pathologic characteristics. Strap muscle invasion alone (code 450 of the CS extension item in the SEER CS version 02.05.50) was categorized as T3b stage, while pericapsular soft tissue or connective tissue invasion was categorized according to tumor size only. Major organ invasion including gross invasion of the subcutaneous soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve from

---

**Figure 1.** Comparison of DSS of the T3b subgroup according to the AJCC 8th TNM staging and modified TNM staging schemas and alluvial plot of restaging according to the two staging schemas. (a,b) Comparison of the disease-specific survival (DSS) between the T3a and T3b stages according to the AJCC 8th TNM staging schema (a) and the modified TNM staging schema (b). Reallocation of the T3a and T3b stages according to the modified TNM staging schema (b) showed significantly different DSS according to tumor size only ($p < 0.001$). (c,d) Comparison of DSS of the T3bNanyM0 group according to the AJCC 8th TNM staging schema (c) and the modified TNM staging schema (d). The T3bNanyM0 group (c) was classified as stage II with the AJCC 8th TNM staging schema. According to the modified TNM staging schema (d), the T3bNanyM0 group was reallocated to either stage I or stage II with statistically significant difference in DSS ($p = 0.015$).
any tumor size was classified as T4a stage per the AJCC 8th TNM staging schema. Likewise, major vessel and/or prevertebral fascia invasions including the encasement of carotid artery or mediastinal vessels from any tumor size were classified as T4b stage.

Based on our hypothesis that minimal and gross strap muscle invasion collectively in the absence of other risk factors does not significantly impact DSS, we suggested a "modified" staging schema thereby discarding strap muscle invasion of any degree from the T staging criteria. Therefore, T3b stage according to the AJCC 8th TNM staging schema were reallocated depending on tumor size only, into either the T1a, T1b, T2, or T3 stage per the modified staging schema. The staging of major adjacent structures extension (i.e., T4a or T4b stages) remained unchanged.

Figure 2. Restaging of the AJCC 8th TNM stages according to the modified TNM staging schema. The alluvial plot shows the reallocation flow for T stages and overall stages according to the modified TNM staging schema. Orange color indicates patients with strap muscle invasion (T3bNanyM0) who were restaged according to tumor size. The number of patients in each T stage of the AJCC 8th TNM staging schema or the modified TNM staging schema are presented along the left and right margins.
Statistical analysis. Statistical analyses were performed using commercially available software (R software, version 3.6.1 (https://www.R-project.org, R Foundation for Statistical Computing, Vienna, Austria) with the application of appropriate R packages (survival, survminer, cmprsk, compareC, ggplot2 and alluvial)24–29. The Cox proportional hazard analysis was used to examine the effects of clinical factors and histopathologic characteristics of DTC on DSS. Competing risk analysis by proportional subdistribution hazards regression modeling was performed26,30. In this study, competing risk was considered death due to other causes since deaths unrelated to DTC may obscure the ability to observe cancer-caused deaths31. Kaplan–Meier estimation and the log rank test were used to assess 10-year DSS probability and DSS curves according to T stages based on either the AJCC 8th TNM staging schema or the modified TNM staging schema. The measure of discrimination for survival prediction was estimated using C-index, and goodness-of-fit for survival prediction was estimated using the PVE for both staging schemas32. All tests were two-sided, and a p-value of less than 0.05 was considered statistically significant.

Received: 23 June 2020; Accepted: 12 October 2020
Published online: 26 October 2020

References
1. Ortiz, S. et al. Extrathyroid spread in papillary carcinoma of the thyroid: clinicopathological and prognostic study. Otolaryngol. Head Neck 124, 261–265 (2001).
2. Andersen, P. E., Kinsella, J., Loree, T. R., Shaha, A. R. & Shah, J. P. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am. J. Surg. 170, 467–470 (1995).
3. Perrier, N. D., Brierley, J. D. & Tuttle, R. M. Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 68, 55–63 (2018).
4. Pontius, L. N. et al. Projecting survival in papillary thyroid cancer: a comparison of the seventh and eighth editions of the American Joint Commission on Cancer/Union for International Cancer Control Staging systems in two contemporary national patient cohorts. Thyroid 27, 1408–1416 (2017).
5. Lamartina, L. et al. 8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect. Endocrinology 25, L7–L11 (2017).
6. Suh, S. et al. Outcome prediction with the revised American Joint Committee on Cancer staging system and American Thyroid Association guidelines for thyroid cancer. Endocrine 58, 495–502 (2017).
7. Shteinshnaider, M. et al. Reassessment of differentiated thyroid cancer patients using the eighth TNM/AJCC classification system: a comparative study. Thyroid 28, 201–209 (2018).
8. Jia, B. J. et al. Characteristics and significance of minimal and maximal extrathyroidal extension in papillary thyroid carcinoma. Oral Oncol. 51, 759–763 (2015).
9. Dionigi, G. et al. Pitfalls in the 2017 TNM classification of thyroid carcinoma. J. Endocr. Surg. 18, 98–109 (2018).
10. Park, S. et al. Prognostic significance of gross extrathyroidal extension invading only strap muscles in differentiated thyroid carcinoma. Br. J. Surg. 105, 1155–1162 (2018).
11. Song, E. et al. A relook at the T stage of differentiated thyroid carcinoma with a focus on gross extrathyroidal extension. Thyroid 29, 202–208 (2019).
12. Verburg, E. A. et al. Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J. Clin. Endocrinol. Metab. 98, 172–180 (2013).
13. Amit, M. et al. Extrathyroidal extension: does strap muscle invasion alone influence recurrence and survival in patients with differentiated thyroid cancer?. Ann. Surg. Oncol. 25, 3380–3388 (2018).
14. Song, E. et al. Clinical significance of gross invasion of strap muscles in patients with 1- to 4-cm-sized papillary thyroid carcinoma undergoing lobectomy. Ann. Surg. Oncol. 26, 4466–4471 (2019).
surveillance, Epidemiology, and End Results (SEER) Program Research Data (1973–2018), released July 2019, based on the November 2018 submission. (National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, 2019).

16. Anderson, K. L. Jr. et al. T1a versus T1b differentiated thyroid cancers: do we need to make the distinction? Thyroid 26, 1046–1052 (2016).

17. Chereau, N. et al. Does extracapsular extension impact the prognosis of papillary thyroid microcarcinoma? Ann. Surg. Oncol. 21, 1659–1664 (2014).

18. Arora, N. et al. Extrathyroidal extension is not all equal: Implications of macroscopic versus microscopic extent in papillary thyroid carcinoma. Surgery 144, 942–947 (2008) (discussion 947–948).

19. Hu, A. et al. Extrathyroidal extension in well-differentiated thyroid cancer: macroscopic vs microscopic as a predictor of outcome. Arch. Otolaryngol. Head Neck Surg. 133, 644–649 (2007).

20. Underwood, H. J. & Patel, K. N. The clinical significance of strap muscle invasion in papillary thyroid cancer on local recurrence: is less surgery warranted? Ann. Surg. Oncol. 26, 4171–4172 (2018).

21. Tam, S. et al. Survival in differentiated thyroid cancer: comparing the AJCC cancer staging seventh and eighth editions. Thyroid 28, 1301–1310 (2018).

22. Khan, Z. A., Mehta, S., Sumathi, N. & Dhiwakar, M. Occult invasion of sternothyroid muscle by differentiated thyroid cancer. Eur. Arch. Otorhinolaryngol. 275, 233–238 (2018).

23. Moran, A., Boonsripitayanon, M. & Zafereo, M. E. ASO Author reflections: strap muscle invasion does not influence recurrence and survival in patients with differentiated thyroid cancer. Ann. Surg. Oncol. 25, 892–893 (2018).

24. Therneau, T. M. A Package for Survival Analysis in S version 2.38 edn (2015).

25. Kassambara, A., Kosinski, M. & Biecek, P. survminer: Drawing Survival Curves using 'ggplot2' R package version 0.4.5 edn (2019).

26. Gray, R. cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2-8 edn (2019).

27. Kang, L., Chen, W., Petrick, N. A. & Gallas, B. D. Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat. Med. 34, 685–703 (2015).

28. Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer, Berlin, 2016).

29. Brunson, J. C. ggalluvial: Alluvial Diagrams in `ggplot2` R package version 0.9.1 edn (2018).

30. Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496–509 (1999).

31. Han, K., Kim, E.-K. & Kwak, J. Y. 1.5–2 cm tumor size was not associated with distant metastasis and mortality in small thyroid cancer: a population-based study. Sci. Rep. 7, 46298 (2017).

32. Schepfer, M. & Stare, J. Explained variation in survival analysis. Stat. Med. 15, 1999–2012 (1996).

Author contributions
J.Y.K., K.H. and J.K.Y. conceived and designed the study. K.H. and J.K.Y. conducted data analyses and prepared the figures. J.K.Y. and J.Y.K. wrote the manuscript text and K.H. provided statistical expertise and aided in interpreting the results. All authors reviewed the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-75161-y.

Correspondence and requests for materials should be addressed to K.H. or J.Y.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020